Doxorubicin induces cell senescence preferentially over apoptosis in the FU-SY-1 synovial sarcoma cell line

Journal of Orthopaedic Research

Volumn 24, Issue 6, 2006, Pages 1163-1169

  Joyner, David E ^a   Bastar, Jeffrey D ^a   Randall, R Lor ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

Apoptosis; Doxorubicin; In vitro; Senescene; Synovial sarcoma

Indexed keywords

BETA GALACTOSIDASE; CASPASE 3; CASPASE 8; CASPASE 9; CATHEPSIN B; COMPLEMENTARY DNA; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYTOCHROME C; DEATH RECEPTOR 5; DOXORUBICIN; FAS ANTIGEN; HERMES ANTIGEN; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL AGING; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA MICROARRAY; DRUG CYTOTOXICITY; DRUG EXPOSURE; ENZYME ACTIVITY; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; SARCOMA CELL; SKIN FIBROBLAST; STATISTICAL SIGNIFICANCE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BETA-GALACTOSIDASE; CELL AGING; CELL LINE, TUMOR; DOXORUBICIN; GENE EXPRESSION PROFILING; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SARCOMA, SYNOVIAL;

EID: 33745098401     PISSN: 07360266     EISSN: None     Source Type: Journal    
DOI: 10.1002/jor.20169     Document Type: Article

References (16)

1. Schwarzbach MH, Eisold S, Burguete T, et al. 2002. Sensitization of sarcoma cells to doxorubicin treatment by concomitant wild-type adeno-associated virus type 2 (AAV-2) infection. Int J Oncol 20:1211-1218.
2. Gewirtz DA. 1999. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharm 57:727-741.
3. Mitsiades N, Yu W-h, Poulaki V, et al. 2001. Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res 61:577-581.
4. Brown JM, Wouters BG. 1999. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 59:1391-1399.
5. Joyner DE, Albritton KH, Bastar JD, et al. 2006. G3139 antisense oligonucleotide directed against anti-apoptotic Bcl-2 enhances doxorubicin cytotoxicity in the FU-SY-1 synovial sarcoma cell line. J Orthop Res 24:474-480.
6. te Poele RH, Okorokov AL, Jardine L, et al. 2002. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res 62:1876-1883.
7. Zheng X, Chou PM, Mirkin BL, et al. 2004. Senescence-initiated reversal of drug resistance specific role of Cathepsin L. Cancer Res 64:1773-1780.
8. Roninson IB. 2003. Tumor cell senescence in cancer treatment. Cancer Res 63:2705-2715.
9. Nishio J, Iwasaki H, Ishiguro M, et al. 2002. Establishment of a new human synovial sarcoma cell line, FU-SY-1, that expresses c-Met receptor and its ligand hepatocyte growth factor. Int J Oncol 21:7-23.
10. Huigsloot M, Tijdens IB, Mulder GJ, et al. 2002. Differential regulation of doxorubicin-induced mitochondrial dysfunction and apoptosis by Bcl-2 in mammary adenocarcinoma (MTLn3) cells. J Biol Chem 277:35869-35879.
11. Tusher VG, Tibshirani R, Chu G. 2001. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98:5116-5121.
12. Storey JD. 2002. A direct approach to false discovery rates. J R Stat Soc 64:479-498.
13. Dolma S, Lessnick SL, Hahn WC, et al. 2003. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell 3:285-296.
14. Müller I, Pfister SM, Grohs U, et al. 2003. Receptor activator of nuclear factor kappaB ligand plays a non-redundant role in doxorubicin-induced apoptosis. Cancer Res 63: 1772-1775.
15. Petak I, Tillman DM, Harwood FG, et al. 2000. Fas-dependent and -independent mechanisms of cell death following DNA damage in human colon carcinoma cells. Cancer Res 60:2643-2650.
16. LeBlanc H, Lawrence D, Varfolomeev E, et al. 2002. Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 8:274-281.